AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03130062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
Study NCT04291248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
Study NCT04291248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.
Study NCT00086970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00086970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Description: Given IV
Study NCT04402970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa Inhalation Solution
Description: Nebulized dornase alfa
Study NCT01457391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Individual CBT, approx. 12 sessions, one session per week
Study NCT01457391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Addiction Counseling
Description: Individual therapy, approx. 12 sessions, one session per week
Study NCT01457391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
Study NCT02171273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Disruption
Description: Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
Study NCT02171273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
Study NCT02171273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
Study NCT01398020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bowel Prep
Description: Subjects will be asked to take 4L of Peglyte the day prior to procedure.
Study NCT01398020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L Bi-Peglyte Bowel Prep
Description: Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
Study NCT03302975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback during treadmill running
Description: Real-time biofeedback of braking forces during running
Study NCT03493087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Menakinon 7
Description: Menakinon 7 - One tablet a day against vitamin K deficiency
Study NCT03493087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet rich in vitamin K
Description: Diet with large content of vegetables and dairy products
Study NCT01436084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB1518
Description: 400 mg taken orally, once daily without regard of food, 28 day cycle.
Study NCT00916279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Paclitaxel-Coated Balloon
Description: PTCA
Study NCT00856960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
Study NCT00856960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
Study NCT00856960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Losartan
Description: Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
Study NCT00856960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to Aliskiren
Description: Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
Study NCT00856960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to Aliskiren
Description: Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
Study NCT00856960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to Losartan
Description: Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
Study NCT00856960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to Losartan
Description: Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
Study NCT01906775 — intervention group
Intervention type: OTHER
Intervention: Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level
Description: Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
Study NCT03023930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Dissemination Practice
Description: Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
Study NCT03023930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation (IF)
Description: IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback.
Study NCT02639611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Post Operative Acupuncture Treatment
Description: acupuncture treatment immediately after surgery (twice a week for 6 weeks)
Study NCT02639611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Acupuncture Treatment
Description: no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
Study NCT03543111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zest
Description: Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
Study NCT03755570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Repeatable Assessment of Neuropsychological Status
Description: Cognitive Function Test (Questionnaire-based)
Study NCT03755570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Cognitive Function Test (Questionnaire-based)
Study NCT00658125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral fornix DBS implantation,
Description: Fornix DBS for Alzheimer Disease
Study NCT04057417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urban Trail
Description: A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
Study NCT03755570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frontal Assessment Battery
Description: Cognitive Function Test (Questionnaire-based)
Study NCT03755570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trail Making Test Part A and B
Description: Cognitive Function Test (Questionnaire-based)
Study NCT03755570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test of Premorbid Functioning
Description: Cognitive Function Test (Questionnaire-based)
Study NCT01357655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
Study NCT01357655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
Study NCT01357655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
Study NCT01043341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educative folder
Description: folder about HPV infection and vaccines
Study NCT01043341 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: educative folder
Description: folder about HPV infection and vaccines
Study NCT02384668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
Study NCT02384668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
Study NCT03344419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: Medication infusion intravenously over 1 hour.
Study NCT03344419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581b
Description: Medication infusion intravenously over 1 hour.
Study NCT03344419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
Study NCT03344419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Description: Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
Study NCT03344419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
Study NCT03344419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Relapse Prevention
Description: Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
Study NCT04453436 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil
Description: Genotipic resistance test
Study NCT03021499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: calcineurin inhibitor
Study NCT03021499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: matching placebo capsule
Study NCT04422548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AI-assisted Colonoscopy
Description: This is a multi-center prospective randomized controlled study comparing real-time AI-assisted colonoscopy versus standard colonoscopy in a real-life setting.
Study NCT04422548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy
Study NCT01177436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Taking of urines
Description: Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
Study NCT01484977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks.
Study NCT00848133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-midvastus surgical approach for total knee arthroplasty
Study NCT00848133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-subvastus surgical approach for total knee arthroplasty
Study NCT00450242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% topical lidocaine ointment
Description: Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
Study NCT00450242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: hydrophilic petrolatum, dime-sized amount, applied nightly.
Study NCT00937261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 2mg - 8mg per day, for the duration of participation in the study
Study NCT00937261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: 6mg - 12mg per day, for the duration of participation in the study
Study NCT03207711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-restricted diet
Description: Education for carbohydrate-restricted diet
Study NCT03207711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Description: Education for carbohydrate-restricted diet
Study NCT03207711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindful eating app-use and instruction
Study NCT03345823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet
Study NCT03345823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet
Study NCT00282295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
Study NCT00282295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra™
Description: Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
Study NCT01181076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized Nutrition
Description: The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
Study NCT00331695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterones caproate
Description: 17 alpha-hydroxyprogesterones caproate
Study NCT02277015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller Laryngoscope
Description: Direct Laryngoscopy
Study NCT02277015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Berci-Kaplan DCI
Description: Videolaryngoscope-1
Study NCT02277015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AirTraq
Description: Videolaryngoscope-2
Study NCT02277015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope GVL
Description: Videolaryngoscope-3
Study NCT02277015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Pentax AWS
Description: Videolaryngoscope-4
Study NCT00121108 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Motavizumab
Description: Intramuscular dose of motavizumab 15 mg/kg will be administered every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
Study NCT00121108 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular dose of placebo matched to motavizumab will be administered every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
Study NCT03588988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine IV infusion
Description: Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
Study NCT03588988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
Study NCT03109379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium-Releasing Intravesical System (TAR-302-5018)
Description: TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Study NCT02108860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
Study NCT02108860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
Study NCT02423551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRE
Description: MRE consumption
Study NCT00729378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skeletal loading
Description: Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
Study NCT01925924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Description: This material contains fluoride
Study NCT01925924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Composite resin
Description: This material does not include fluoride
Study NCT04383379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention group
Description: The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
Study NCT02246582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Enlite 3
Description: Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen \& arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
Study NCT02246582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Guardian Mobile App
Study NCT02246582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 640G Insulin Pump